PRO 2000

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PRO 2000
Systematic (IUPAC) name
Sodium 2-naphthalenesulfonate, polymer with formaldehyde
Identifiers
CAS Number 29321-75-3
ChemSpider none
NIAID ChemDB 032942
Synonyms 2-Naphthalenesulfonic acid, sodium salt, polymer with formaldehyde
Chemical data
Formula (C10H8O3S.CH2O.Na)x
Molar mass Approximately 5 kg/mol

PRO 2000 is an experimental vaginal microbicide which has been proposed as a preventative medicine for reducing the risk of contracting HIV. It has never been recommended as an effective medicine to be used for any purpose. Some clinical trials have shown that under some conditions it may provide some protection against HIV.

History[edit]

Endo Pharmaceuticals manufactures the drug.[1]

Efficacy[edit]

Animal testing studies done on macaques have shown that PRO 2000 is effective in preventing the transmission of HIV. Other studies have given supportive evidence that the product is safe in humans and would be an appropriate candidate for testing.[2]

A phase III clinical trial of 9385 women in sub-Saharan Africa showed that PRO 2000 was not effective in preventing transmission of HIV.[3]

References[edit]

  1. ^ "AIDSinfo - HIV/AIDS Drug Information - PRO 2000". aidsinfo.nih.gov. 2011. Archived from the original on October 17, 2011. Retrieved 20 November 2011. 
  2. ^ Patton, D. L.; Cosgrove Sweeney, Y. T.; Paul, K. J. (2008). "A Summary of Preclinical Topical Microbicide Vaginal Safety and Chlamydial Efficacy Evaluations in a Pigtailed Macaque Model". Sexually Transmitted Diseases. 35 (10): 889–897. doi:10.1097/OLQ.0b013e31817dfdb8. PMID 18607310. 
  3. ^ McCormack, S.; Ramjee, G.; Kamali, A.; Rees, H.; Crook, A. M.; Gafos, M.; Jentsch, U.; Pool, R.; Chisembele, M.; Kapiga, S.; Mutemwa, R.; Vallely, A.; Palanee, T.; Sookrajh, Y.; Lacey, C. J.; Darbyshire, J.; Grosskurth, H.; Profy, A.; Nunn, A.; Hayes, R.; Weber, J. (2010). "PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial". The Lancet. 376 (9749): 1329. doi:10.1016/S0140-6736(10)61086-0.